Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Effects of Whole-Body High-Intensity Interval Training on Fitness in Overweight Adults (WB-HIIT)

maanantai 11. toukokuuta 2026 päivittänyt: Malgorzata Klass, Université Libre de Bruxelles

Effects of a Whole-body High-intensity Interval Training on Cardiorespiratory Fitness, Musculoskeletal Fitness, Body Composition and Blood Parameters in Overweight Subjects

This study aims to evaluate the effects of a supervised whole-body high-intensity interval training (WB-HIIT) program on physical fitness and health outcomes in adults with overweight and obesity. WB-HIIT is a practical and time-efficient training modality based on body-weight exercises performed at high intensity with short recovery intervals. It may offer an accessible approach for improving health in individuals with excess body weight.

Participants aged 18 to 55 years with a body mass index (BMI) between 25 and 35 kg/m² will take part in a supervised 10-week WB-HIIT program, performed in small groups and led by trained exercise professionals. Before and after the intervention, participants will undergo assessments including DXA-based body composition analysis, fasting blood sampling, muscular strength testing, a Chester step test, a maximal graded treadmill exercise test with gas-exchange analysis to determine VO₂peak, and functional evaluations (chair-stand, arm-curl, and 6-minute walk test). Physical activity and dietary intake will also be recorded.

The primary objective of the study is to assess whether WB-HIIT improves cardiorespiratory fitness (VO₂peak) in adults with overweight. Secondary objectives include evaluating changes in muscular strength, body composition, metabolic markers, and functional capacity.

The results may help determine whether an equipment-free WB-HIIT program can serve as an effective and accessible training approach for improving health and physical fitness in adults with overweight and obesity.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

This study investigates the physiological, functional, and metabolic effects of a supervised whole-body high-intensity interval training (WB-HIIT) program conducted entirely in person in adults with overweight and obesity.

Overweight and obesity are associated with decreased cardiorespiratory fitness, metabolic impairments, and increased risk of chronic diseases. In contrast, regular physical activity is known to improve cardiorespiratory fitness, metabolic health, body composition, strength, and quality of life. WB-HIIT, which involves body-weight exercises performed at high intensity with controlled recovery intervals, provides a time-efficient, equipment-free training modality that can be adapted for individuals with excess body weight.

A total of 40 adults aged 18 to 55 years with a BMI between 25 and 35 kg/m² will be recruited and allocated to an intervention and control group. In the intervention group, participants will complete a 10-week supervised WB-HIIT program consisting of 2 to 3 sessions per week. Training sessions will include 8 to 12 whole-body exercises targeting major muscle groups, performed in intervals lasting 20 to 60 seconds with recovery periods adjusted according to participant progression. Intensity will be monitored through heart rate and perceived exertion (Borg CR-10 scale), and progression will be achieved by modifying the number of sets, exercise complexity, and work-to-rest ratio.

All participants will undergo comprehensive pre- and post-intervention evaluations. Body composition will be measured using DXA, and anthropometric measurements will include waist circumference and BMI. Cardiometabolic health will be assessed through fasting blood sampling measuring glucose, insulin, HbA1c, lipid profile, hepatic markers, and additional exploratory biomarkers. Cardiorespiratory fitness will be evaluated using a maximal graded treadmill test with gas exchange analysis to determine VO₂peak and the Chester step test. Functional performance will be assessed through the 30-second chair-stand test, arm-curl test, and 6-minute walk test. Muscular strength will be evaluated through 3-repetition maximum (3-RM) testing and fatigue protocols at 60% of 1-RM for the leg-press and bench-press exercises. Physical activity and dietary habits will also be evaluated before and after the intervention.

The primary outcomes of the study are the changes in VO₂peak and muscle strength following the intervention. Secondary outcomes include changes in body composition, metabolic parameters, and functional capacity. Statistical analyses will include repeated-measures ANOVA and between-group comparisons using parametric or non-parametric methods as appropriate.

This study aims to deepen understanding of the effects of supervised WB-HIIT in overweight adults and to identify practical, scalable training methods that can be implemented in community or clinical settings. The findings may guide the development of accessible exercise-based health strategies for improving fitness and metabolic health in this population.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

40

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

  • Belgia
      • Brussels, Belgia
        • Rekrytointi
        • Université libre de Bruxelles (ULB)

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  • Adults aged 18 to 55 years.
  • Body mass index (BMI) between 25 and 35 kg/m².
  • Able to provide written informed consent.
  • Able to safely participate in high-intensity interval training.
  • For participants with BMI > 30 kg/m²: medical clearance from their general practitioner.

Exclusion Criteria:

  • BMI < 25 or > 35 kg/m².
  • Presence of any chronic medical condition other than overweight/obesity.
  • Known cardiovascular, metabolic, respiratory, or musculoskeletal disease that contraindicates high-intensity exercise.
  • Pregnancy.
  • Inability to perform exercise testing or complete the WB-HIIT program.
  • Any condition judged by investigators to interfere with participation or data interpretation.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Perustiede
  • Jako: Ei satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: WB-HIIT Intervention
A supervised whole-body high-intensity interval training (WB-HIIT) program performed in small groups. Participants complete 2 to 3 sessions per week for 10 weeks. Each session includes a warm-up followed by 8 to 12 whole-body exercises performed at high intensity for 20-60 seconds with recovery periods of 20-60 seconds. Progression is applied by adjusting exercise complexity, number of sets, and work-to-rest ratio. Heart rate and perceived exertion (Borg CR-10 scale) are monitored.
Käyttäytyminen: Whole-Body High-Intensity Interval Training (WB-HIIT)
A structured WB-HIIT program using body-weight exercises such as squats, lunges, mountain climbers, and similar multi-joint movements. Sessions last 35-50 minutes and include 3 to 4 sets of interval blocks performed at high intensity. The training is supervised by qualified exercise professionals.
Ei väliintuloa: Control Group
Participants in the control group do not receive structured exercise training. They maintain their usual lifestyle and complete the same pre- and post-intervention assessments as the intervention group.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Peak oxygen consumption (VO₂peak)
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Peak oxygen consumption (VO₂peak) will be measured during a maximal graded treadmill exercise test with gas analysis to assess changes in cardiorespiratory fitness following the 10-week WB-HIIT program. VO₂peak will be expressed in mL·kg-¹·min-¹.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Muscular strength
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Maximal dynamic strength will be assessed using 3-repetition maximum (3-RM) tests on the leg press and bench press.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Estimated VO₂max from the Chester Step Test
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Cardiorespiratory fitness will also be estimated using the Chester Step Test to evaluate submaximal aerobic capacity.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Body composition
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Total and segmental (i.e., arms, legs and trunk) body fat mass, lean mass, and visceral fat will be assessed using dual-energy X-ray absorptiometry (DXA). They will all be expressed in kg.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Muscular endurance (fatigue tests at 60% 1-RM)
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Muscular endurance will be evaluated by recording the number of repetitions performed at 60% of the estimated 1-RM for leg press and bench press.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Functional performance (chair-stand test)
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Lower-body function will be assessed using the 30-second chair-stand test.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Upper-body functional performance (arm-curl test)
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Upper-body functional performance will be measured using the 30-second arm-curl test with standardized weights (2 kg for women, 4 kg for men).
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Functional capacity (6-minute walk test)
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Functional aerobic capacity will be assessed during a standardized 6-minute walk test, recording distance walked and recovery heart rate.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Blood biomarkers
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Fasting blood markers will include glucose, insulin, HbA1c, lipid profile (total cholesterol, HDL, triglycerides), liver enzymes, and exploratory metabolic biomarkers.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Waist circumference
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Waist circumference will be measured at the midpoint between the lower rib and iliac crest to assess changes in abdominal adiposity.
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Physical activity level using the International Physical Activity Questionnaire
Aikaikkuna: At Baseline

Self-reported physical activity will be assessed using the short format of the International Physical Activity Questionnaire (IPAQ-short form).

The IPAQ-short form assesses physical activity over the past seven days by recording time spent in vigorous activity, moderate activity, walking, and sitting.

It converts the time spent in different physical activity intensities into total energy expenditure, expressed in MET-minutes per week. Walking, moderate activity, and vigorous activity are assigned MET values of 3.3, 4.0, and 8.0 respectively.

Based on an individual's responses, the physical activity level can be expressed continuously (MET-min per week), or categorised has low, moderate and high (please refer to: https://sites.google.com/view/ipaq/score). Higher values/scores mean a higher level of physical activity.
At Baseline
Dietary intake (3-day food record)
Aikaikkuna: The outcome will be assessed once at baseline and once during the week following completion of the whole-body high-intensity interval training intervention.
Dietary intake will be evaluated using a 3-day food record analyzed with standardized nutrition software.
The outcome will be assessed once at baseline and once during the week following completion of the whole-body high-intensity interval training intervention.
Weight
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Weight will be measured using a scale (in kilograms).
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Height
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Height will be measured using stadiometer (in meters).
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Body mass index
Aikaikkuna: The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.
Weight and height will be combined to report body mass index, expressed in kg/m²
The outcome will be assessed once at baseline and within 72 hours after the last session of the whole-body high-intensity interval training intervention.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Université Libre de Bruxelles

Tutkijat

  • Opintojohtaja: Malgorzata Klass, PhD; Prof., Université libre de Bruxelles (ULB), Research Unit in Cardio-respiratory Physiology, Exercise & Nutrition

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 9. marraskuuta 2022

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. kesäkuuta 2026

Opintojen valmistuminen (Arvioitu)

Maanantai 1. kesäkuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 19. helmikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 11. toukokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 13. toukokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 13. toukokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 11. toukokuuta 2026

Viimeksi vahvistettu

Perjantai 1. toukokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • ULB-WBHIIT-OVERWEIGHT-2026-01
  • P2022-344 (Muu tunniste: Comité d'Ethique de l'Hôpital Erasme)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

Individual participant data will not be shared due to confidentiality requirements and restrictions imposed by the ethics committee.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa